MedPath

Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies

Terminated
Conditions
Neuronopathy
Registration Number
NCT02514109
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

The diagnosis of sensory neuronopathy is difficult to establish because the only certainty criterion is based on the detection of specific lesions in the posterior spinal ganglion which is usually not possible. There is to date no clinical and electrophysiological criteria or validated biomarker for the diagnosis of this type of neuropathy. In a retrospective study, we analyzed the files of patients with peripheral sensory neuronopathy certain and established clinical and electrophysiological diagnostic criteria for sensitive neuronopathy. We therefore wish now validate these criteria and investigate possible associated antibodies on a prospective cohort of patients.

Detailed Description

All the patients (patient group and control) will be included in the study after giving their consent. The clinical, biological and electrophysiological data concerning the neuropathy will be collected. There is no specific follow-up for the study.

Blood samples will be retrospectively analyzed for antibody screening.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • A :Patients Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.

B :Controls Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.

Exclusion Criteria
  • Patient with a sensory-motor neuropathy or incomplete clinical evaluation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Likelihood ratio diagnostic criteria established on the study populationbaseline

The set of diagnostic criteria giving the best sensitivity and specificity for a diagnosis of sensory neuronopathy (composite measure)

Secondary Outcome Measures
NameTimeMethod
Identified antibodiesbaseline

Sensibility and specificity of identified antibodies (composite measure)

Trial Locations

Locations (12)

CHU Angers

🇫🇷

Angers, France

CHU Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

CHU de Grenoble

🇫🇷

Grenoble, France

Hospices Civils de Lyon

🇫🇷

Lyon, France

AP-HM

🇫🇷

Marseille, France

CHU de Montpellier

🇫🇷

Montpellier, France

CHU de Nimes

🇫🇷

Nimes, France

Hopital Pitie Salpetriere

🇫🇷

Paris, France

CHU Poitiers

🇫🇷

Poitiers, France

Chu Saint-Etienne

🇫🇷

Saint-etienne, France

Scroll for more (2 remaining)
CHU Angers
🇫🇷Angers, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.